Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, crossover TQT study effects of nebulized ensifentrine on measures of cardiac conduction compared with placebo in healthy volunteers

Next Previous
X
Search
Trial Profile

Randomized, double-blind, crossover TQT study effects of nebulized ensifentrine on measures of cardiac conduction compared with placebo in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensifentrine (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Verona Pharma

    • Most Recent Events

    • 09 May 2022 According to a Verona Pharma media release, data from this trial will be published at the American Thoracic Society International Conference (ATS) 2022
    • 21 Dec 2021 New trial record
    • 16 Dec 2021 According to a Verona Pharma media release, as per USFDA one study was required to support most New Drug Applications for potential new medications. The protocol of this study was reviewed by the FDA prior to commencing the study, and these results will support the planned submission for ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top